FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891139352> ?p ?o ?g. }

• W2891139352 endingPage "e021447" @default.
• W2891139352 startingPage "e021447" @default.
• W2891139352 abstract "Objective These analyses aim to comparatively evaluate the persistence on treatment of different biological disease-modifying antirheumatic drugs (bDMARDs) when administered in monotherapy compared with combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) patients receiving first-line biologics. Design This is a retrospective observational study on Administrative Healthcare Databases. Methods Data were extracted from healthcare databases of the Lombardy Region, Italy (2004–2013), as a part of the RECord-linkage On Rheumatic Diseases study, on behalf of the Italian Society for Rheumatology. Analyses included patients with RA starting first-line approved course of bDMARDs and evaluated drug survival by using Cox proportional hazard models. Results are presented as HRs and 95% CI, crude and adjusted for prespecified confounders (age, sex, disease duration, Charlson Comorbidity Index (CCI), previous infections, use of concomitant glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs)). Results 4478 patients with RA were included (17.84% monotherapy). Etanercept, adalimumab and infliximab were the most prescribed first-line biologics. bDMARD monotherapy was associated with longer disease duration, higher CCI, lower glucocorticoids and NSAIDs use. Compared with monotherapy, combination associated with a lower risk of failure (adjusted HR 0.79, 95% CI 0.72 to 0.88). Among monotherapies, considering etanercept as reference, adalimumab (1.28, 95% CI 1.03 to 1.59) and infliximab (2.41, 95% CI 1.85 to 3.15) had higher risk of failure. Concomitant methotrexate (0.78, 95% CI 0.70 to 0.87), leflunomide (0.80, 95% CI 0.65 to 0.98) or csDMARD combinations (0.77, 95% CI 0.68 to 0.87) reduced the risk of bDMARD withdrawal. Conclusion Adalimumab and infliximab monotherapies show lower retention rate compared with etanercept. The relatively small number of therapeutic courses different from tumour necrosis factor (TNF) inhibitors makes more difficult to achieve conclusive results with other biologics. Concomitant methotrexate, leflunomide and csDMARDs combination associate with longer survival on bDMARD. Our data confirm the effectiveness of the current practices in the choice of etanercept as first-line anti-TNF monotherapy and strengthen the currently recommended use of bDMARDs in combination with csDMARDs." @default.
• W2891139352 created "2018-09-27" @default.
• W2891139352 creator A5006082336 @default.
• W2891139352 creator A5037295594 @default.
• W2891139352 creator A5058604755 @default.
• W2891139352 creator A5064303070 @default.
• W2891139352 creator A5069264564 @default.
• W2891139352 creator A5086941743 @default.
• W2891139352 date "2018-09-01" @default.
• W2891139352 modified "2023-10-16" @default.
• W2891139352 title "Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases" @default.
• W2891139352 cites W1526073830 @default.
• W2891139352 cites W1526426863 @default.
• W2891139352 cites W1585721025 @default.
• W2891139352 cites W1678732033 @default.
• W2891139352 cites W1838152093 @default.
• W2891139352 cites W1874236485 @default.
• W2891139352 cites W1934079113 @default.
• W2891139352 cites W2010363255 @default.
• W2891139352 cites W2010937399 @default.
• W2891139352 cites W2018118744 @default.
• W2891139352 cites W2024549371 @default.
• W2891139352 cites W2030855147 @default.
• W2891139352 cites W2034100892 @default.
• W2891139352 cites W2039095216 @default.
• W2891139352 cites W2049625559 @default.
• W2891139352 cites W2084560920 @default.
• W2891139352 cites W2085125550 @default.
• W2891139352 cites W2092086105 @default.
• W2891139352 cites W2096545621 @default.
• W2891139352 cites W2098972068 @default.
• W2891139352 cites W2102207725 @default.
• W2891139352 cites W2106962952 @default.
• W2891139352 cites W2110345763 @default.
• W2891139352 cites W2112234440 @default.
• W2891139352 cites W2120143305 @default.
• W2891139352 cites W2120393706 @default.
• W2891139352 cites W2124045236 @default.
• W2891139352 cites W2127294373 @default.
• W2891139352 cites W2129168200 @default.
• W2891139352 cites W2129400639 @default.
• W2891139352 cites W2139201413 @default.
• W2891139352 cites W2141308695 @default.
• W2891139352 cites W2141395406 @default.
• W2891139352 cites W2151858167 @default.
• W2891139352 cites W2164312146 @default.
• W2891139352 cites W2166232525 @default.
• W2891139352 cites W2170660004 @default.
• W2891139352 cites W2230391954 @default.
• W2891139352 cites W2262131072 @default.
• W2891139352 cites W2471789670 @default.
• W2891139352 cites W2485191439 @default.
• W2891139352 cites W2511774499 @default.
• W2891139352 cites W2515193832 @default.
• W2891139352 cites W2530829879 @default.
• W2891139352 cites W2564331065 @default.
• W2891139352 cites W2579361561 @default.
• W2891139352 cites W2585172639 @default.
• W2891139352 cites W2625653094 @default.
• W2891139352 cites W2743282448 @default.
• W2891139352 cites W2758506768 @default.
• W2891139352 cites W2806643091 @default.
• W2891139352 doi "https://doi.org/10.1136/bmjopen-2017-021447" @default.
• W2891139352 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6144331" @default.
• W2891139352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30206082" @default.
• W2891139352 hasPublicationYear "2018" @default.
• W2891139352 type Work @default.
• W2891139352 sameAs 2891139352 @default.
• W2891139352 citedByCount "28" @default.
• W2891139352 countsByYear W28911393522018 @default.
• W2891139352 countsByYear W28911393522019 @default.
• W2891139352 countsByYear W28911393522020 @default.
• W2891139352 countsByYear W28911393522021 @default.
• W2891139352 countsByYear W28911393522022 @default.
• W2891139352 countsByYear W28911393522023 @default.
• W2891139352 crossrefType "journal-article" @default.
• W2891139352 hasAuthorship W2891139352A5006082336 @default.
• W2891139352 hasAuthorship W2891139352A5037295594 @default.
• W2891139352 hasAuthorship W2891139352A5058604755 @default.
• W2891139352 hasAuthorship W2891139352A5064303070 @default.
• W2891139352 hasAuthorship W2891139352A5069264564 @default.
• W2891139352 hasAuthorship W2891139352A5086941743 @default.
• W2891139352 hasBestOaLocation W28911393521 @default.
• W2891139352 hasConcept C126322002 @default.
• W2891139352 hasConcept C167135981 @default.
• W2891139352 hasConcept C198451711 @default.
• W2891139352 hasConcept C207103383 @default.
• W2891139352 hasConcept C2775905006 @default.
• W2891139352 hasConcept C2777138892 @default.
• W2891139352 hasConcept C2777226972 @default.
• W2891139352 hasConcept C2777575956 @default.
• W2891139352 hasConcept C2779134260 @default.
• W2891139352 hasConcept C2779384505 @default.
• W2891139352 hasConcept C2780132546 @default.
• W2891139352 hasConcept C41008148 @default.
• W2891139352 hasConcept C44249647 @default.
• W2891139352 hasConcept C71924100 @default.
• W2891139352 hasConcept C77088390 @default.

• next